Navigation

Personal tools

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit https://cc.nih.gov/.

Updates regarding government operating status and resumption of normal operations can be found at https://USA.gov/.

You are here: Home / Biomarkers / RGS5

RGS5

Basics

Aliases:
This biomarker is also known as:
  • MST092,
  • regulator of G-protein signaling 5,
  • MSTP092,
  • MSTP106,
  • MST129,
  • MST106,
  • MSTP129,
  • MSTP032,
  • regulator of G-protein signalling 5,

Description…

RGS5 is a member of the regulators of G protein signaling (RGS) family, which are signal transduction molecules that are involved in the regulation of heterotrimeric G proteins by acting as GTPase activators. RGS5 has been found to be involved in tumor angiogenesis and to antagonize the angiogenic effect of VEGF. Multiple alternatively spliced transcript variants have been found.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: RGS5

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

RGS5 has been found to be up-regulated in many types of malignant cells, including breast cancer.

Performance Comment

RGS5 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Biomuta

Mutation Statistics

Gene Name: RGS5
UniProt Accession #: O15539
Mutated Sites Count: 65
Associated Pubmed ID Count 5
CancerDO Count 15
Affected Protein Function Sites Count: 1

View in BioMuta